| Summary: | 碩士 === 國立交通大學 === 生物科技學系 === 105 === Small cell lung cancer (SCLC) is a devastating disease and a major therapeutic burden with poor survival rates. Chemotherapy remains the cornerstone of treatment for both limited-stage and extensive-stage SCLC. Cancer cells display high rates of aerobic glycolysis in comparison with their non-transformed counterparts. So, targeting glycolysis for cancer treatment has been explored previously as a therapeutic approach. The aim of this study is to explore the anticancer activity of a 2-deoxy-glucose in SCLC cell lines and xenografts, by performing assays to assess cell proliferation, apoptosis, signaling pathways, and cell cycle progression. Furthermore, the enhanced efficacy of the 2-deoxy-glucose in combination with either cisplatin or etoposide has been investigated. Our preliminary results showed that the 2-deoxy-glucose dose-dependently inhibited cell viability and induced programmed-cell death in SCLC cells. The 2-deoxy-glucose also significantly affected critical signaling pathways (AKT, ERK, S6). In combination treatments, the 2-deoxy-glucose plus cisplatin or etoposide has shown significant anti-proliferative activity as compared with single agent alone. In the future, we will investigate whether the 2-deoxy-glucose has an impact in cell cycle progression. In addition, we will assess the anti-tumor activity of the 2-deoxy-glucose alone or in combination with chemotherapeutic agent in H209 xenografted nude mice. In summary, results from our studies have suggested that 2-deoxy-glucose could serve as a promising class of anti-tumor agent for future SCLC treatments.
|
|---|
